Advertisement
Vaccines
Subscribe to Vaccines

The Lead

Toward a cocaine vaccine to help addicts kick the habit

January 22, 2015 8:44 am | by American Chemical Society | News | Comments

In their decades-long search for vaccines against drugs of abuse, scientists have hit upon a new approach to annul cocaine’s addictive buzz. They report in Molecular Pharmaceutics that their strategy, which they tested on mice, harnesses a bacterial protein to trigger an immune system attack on the drug if it enters the body. This response could dull cocaine’s psychotropic effects and potentially help users of the drug kick the habit.

Flu vaccine 23% effective

January 16, 2015 2:04 pm | by Mike Stobbe, AP Medical Writer, Associated Press | News | Comments

As predicted, this year's flu vaccine is doing a pretty crummy job. It's only 23% effective,...

New approach may lead to inhalable vaccines for influenza, pneumonia

January 8, 2015 9:29 am | by Matt Shipman, News Services, North Carolina State Univ. | News | Comments

Researchers at North Carolina State Univ. and the Univ. of North Carolina at Chapel Hill have...

CDC: Flu season continues to worsen, could peak this month

January 5, 2015 5:35 pm | by By Mike Stobbe, AP Medical Writer, Associated Press | News | Comments

The flu is now widespread in all but seven states, and hospitalization rates match the dismal...

View Sample

FREE Email Newsletter

HIV vaccines should avoid viral target cells

January 5, 2015 8:09 am | by Lisa Newbern, Emory Univ. | News | Comments

Vaccines designed to protect against HIV can backfire and lead to increased rates of infection. This unfortunate effect has been seen in more than one vaccine clinical trial. Scientists at Emory Univ. have newly published results that support a straightforward explanation for the backfire effect: vaccination may increase the number of immune cells that serve as viral targets.

Grant Supports Use of Data Science to Optimize HIV Care

December 30, 2014 9:30 am | by Brown University | News | Comments

HIV can be treated, but not every infection responds the same way. Treatment requires monitoring and testing, a practice that can become expensive for health care systems in the developing world.                                    

Improving Patient Access through Public-Private Partnerships

December 15, 2014 1:20 pm | by Brian Goff, Global Franchise Head, Hemophilia, Baxter BioScience | Articles | Comments

As the health care industry is undergoing a rapid transformation driven by evolving economic and regulatory demands, the biopharmaceutical industry also faces numerous challenges in meeting the needs of patients around the globe. Emerging markets are faced with the challenges of ensuring access to innovative, personalized treatments for patients with critical or rare conditions.

Advertisement

Ebola vaccine trial suspended after side effects

December 11, 2014 12:12 pm | by Associated Press | News | Comments

Swiss researchers have suspended the testing of one of the leading Ebola vaccine candidates after some volunteers reported unexpected side effects.                             

Injectable 3-D vaccines could fight cancer, infectious diseases

December 8, 2014 4:13 pm | by Kat J. McAlpine, Wyss Institute for Biologically Inspired Engineering | News | Comments

One of the reasons cancer is so deadly is that it can evade attack from the body's immune system, which allows tumors to flourish and spread. Scientists can try to induce the immune system, known as immunotherapy, to go into attack mode to fight cancer and to build long lasting immune resistance to cancer cells. Now, researchers have developed a non–surgical injection of programmable biomaterial to do so.

Flu vaccine doesn’t protect against most dominant strain

December 5, 2014 9:08 am | by Associated Press, Mike Stobbe | News | Comments

The flu vaccine may not be very effective this winter, according to U.S. health officials who worry this may lead to more serious illnesses and deaths. Flu season has begun to ramp up, and officials say the vaccine does not protect well against the dominant strain seen most commonly so far this year. That strain tends to cause more deaths and hospitalizations, especially in the elderly.

Ebola vaccine seems safe in first-stage testing

November 26, 2014 6:00 pm | by By Lauran Neergaard - AP Medical Writer - Associated Press | News | Comments

An experimental Ebola vaccine appears safe and triggered signs of immune protection in the first 20 volunteers to test it, U.S. researchers reported. The vaccine is designed to spur the immune system's production of anti-Ebola antibodies, and people developed them within four weeks of getting the shots at the National Institutes of Health.

A hybrid vehicle that delivers DNA

November 26, 2014 7:46 am | by Cory Nealon, Univ. at Buffalo | News | Comments

A new hybrid vehicle is under development. Its performance isn’t measured by the distance it travels, but rather the delivery of its cargo: vaccines that contain genetically engineered DNA to fight HIV, cancer, influenza and other maladies. The technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite much research, have yet to make a significant impact in the treatment of major illnesses.

Advertisement

Government wants more clinical trial results made public

November 19, 2014 3:00 pm | by Lauran Neergaard - AP Medical Writer - Associated Press | News | Comments

The government proposed new rules Wednesday to make it easier for doctors and patients to learn if clinical trials of treatments worked or not. Thousands of Americans participate in clinical trials every year, testing new treatments, comparing old ones or helping to uncover general knowledge about health. Many of the studies are reported in scientific journals and trumpeted in the news.

Biochemists build largest synthetic molecular “cage” ever

November 19, 2014 10:26 am | by Stuart Wolpert, Univ. of California, Los Angeles | News | Comments

Univ. of California, Los Angeles biochemists have created the largest-ever protein that self-assembles into a molecular “cage.” The research could lead to synthetic vaccines that protect people from the flu, HIV and other diseases. At a size hundreds of times smaller than a human cell, it also could lead to new methods of delivering pharmaceuticals inside of cells, or to the creation of new nanoscale materials.

Study will test survivors' blood to treat Ebola

November 18, 2014 11:00 pm | by Marilynn Marchione - AP Chief Medical Writer - Associated Press | News | Comments

A coalition of companies and aid groups announced plans Tuesday to test experimental drugs and collect blood plasma from Ebola survivors to treat new victims of the disease in West Africa. Plasma from survivors contains antibodies, substances the immune system makes to fight the virus.

Scientists reveal weak spots in Ebola’s defenses

November 18, 2014 9:27 am | by The Scripps Research Institute | News | Comments

Scientists at The Scripps Research Institute have identified weak spots on the surface of Ebola virus that are targeted by the antibodies in ZMapp, the experimental drug cocktail administered to several patients during the recent Ebola outbreak. The study provides a revealing 3-D picture of how the ZMapp antibodies bind to Ebola virus.

Ebola workers ask Congress for help

November 12, 2014 3:58 am | by Lauran Neergaard - Associated Press - Associated Press | News | Comments

Health workers on the front line of the Ebola crisis say the need for urgent help isn't letting up, as Congress begins considering President Barack Obama's $6.2 billion emergency aid request to fight the disease. Despite reports that the number of infections is slowing in some parts of West Africa, cases still are rising in other areas.

Advertisement

Inhaled Ebola vaccine may offer long-term protection from virus

November 3, 2014 1:43 pm | by J.B. Bird, Univ. of Texas at Austin | News | Comments

A potentially breathable, respiratory vaccine in development has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Results from a recent pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long lasting, which could have significant global implications in controlling future outbreaks.

EU seeking to create $1.27 billion Ebola fund

October 20, 2014 10:27 am | by Raf Casert - Associated Press - Associated Press | News | Comments

European Union nations are working to reach 1 billion euros ($1.27 billion) in aid by the end of the week to fight Ebola in West Africa and are seeking a common approach to the crisis.EU foreign ministers began a week of talks Monday so their 28 leaders can agree by Friday on better measures to fight Ebola, anything from financial aid to common repatriation procedures, more Ebola treatment facilities and better training for health workers.

ORNL joins global fight against polio

October 17, 2014 8:36 am | by Christopher R. Samoray, Oak Ridge National Laboratory | News | Comments

The new Urban Dynamics Institute at Oak Ridge National Laboratory is working with the Bill & Melinda Gates Foundation to aid polio vaccination efforts in developing countries. Teams at the institute will apply big data analysis to population dynamics in Nigeria, allowing polio vaccination crews to better estimate the amount of vaccine needed and to target areas of priority, saving time and money in eradicating the disease.

What to do about the dwindling stock of antibiotics

October 13, 2014 8:57 am | by Diana Lutz, Washington Univ. in St. Louis | News | Comments

The Centers for Disease Control and Prevention has said that at least 2 million Americans are sickened by antibiotic resistant infections each year and survive. Twenty-three thousand die. These experiences leave deep impressions not just on the patients but on their family and friends.

Molecular structure of Hep C envelope protein unveiled

October 10, 2014 9:09 am | by Laura Mgrdichian, Brookhaven National Laboratory | News | Comments

Hepatitis C, an infectious disease of the liver caused by the hepatitis C virus (HCV), affects 160 million people worldwide. There’s no vaccine for HCV and the few treatments that are available do not work on all variants of the virus. Before scientists can develop potential vaccines and additional therapies they must first thoroughly understand the molecular-level activity that takes place when the virus infects a host cell.

Do-it-yourself flu vaccine? Study shows it works

October 8, 2014 10:40 am | by Marilynn Marchione - AP Chief Medical Writer - Associated Press | News | Comments

A study suggests that do-it-yourself flu vaccine might be possible. Researchers found that military folks who squirted a nasal vaccine up their noses were as well-protected as others who got it from health workers. The study leader says there is no reason that ordinary people could not be taught to give the vaccine, especially for children who might be less scared if they received it from mom or dad.

Ebola's victims may include dog in Spain

October 7, 2014 7:38 pm | by Marilynn Marchione - AP Chief Medical Writer - Associated Press | News | Comments

Ebola's victims may include a dog named Excalibur. Officials in Madrid got a court order to euthanize the pet of a Spanish nursing assistant with Ebola because of the chance the animal might spread the disease. At least one major study suggests that dogs can be infected with the deadly virus without having symptoms. But whether or how likely they are to spread it to people is less clear.

Researchers turn computers into powerful allies in the fight against AIDS

October 7, 2014 9:54 am | News | Comments

Until now, researchers searching for compounds that have the potential to become a new HIV drug have been hampered by slow computers and inaccurate prediction models. Now, researchers in Denmark have developed an effective model based on quantum mechanics and molecular mechanics that has found, out of a half-million compounds, 14 of interest in just weeks.

Liquid DNA behind virus attacks

October 6, 2014 11:48 am | News | Comments

According to two recent studies, viruses can convert their DNA from solid to fluid form, explaining how viruses manage to eject DNA into the cells of their victims. The researchers in one study, which focused on herpes infections, say the discovery was surprising: No one was previously aware of the “phase transition” from solid to fluid form in virus DNA.

“Stealth” nanoparticles could improve cancer vaccines

October 2, 2014 8:01 am | News | Comments

Cancer vaccines have recently emerged as a promising approach for killing tumor cells before they spread. But so far, most clinical candidates haven’t worked that well. Now, scientists have developed a new way to deliver vaccines that successfully stifled tumor growth when tested in laboratory mice. And the key is in the vaccine’s unique stealthy nanoparticles.

Government confirms first case of Ebola in U.S.

September 30, 2014 7:38 pm | by David Warren - Associated Press - Associated Press | News | Comments

Federal health officials on Tuesday confirmed the first case of Ebola diagnosed in the U.S., a patient who recently traveled from Liberia to Dallas and a sign of the far-reaching impact of the out-of-control epidemic in West Africa. The unidentified patient was critically ill and has been in isolation at Texas Health Presbyterian Hospital since Sunday, officials said.

A new way to prevent the spread of devastating diseases

September 19, 2014 8:01 am | by Kimm Fesenmaier, Caltech | Videos | Comments

For decades, researchers have tried to develop broadly effective vaccines to prevent the spread of illnesses such as HIV, malaria and tuberculosis. While limited progress has been made along these lines, there are still no licensed vaccinations available that can protect most people from these devastating diseases. So what are immunologists to do when vaccines just aren't working?

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading